Clinical efficacy of istradefylline on lower urinary tract symptoms in Parkinson’s disease: A prospective study
Objective: The aim of the present study was to determine the effects of istradefylline, adenosine A2A receptor antagonist on lower urinary tract symptoms (LUTS) in…Validation study of Parkinson anxiety scale, Czech version
Objective: The study aims to evaluate psychometric properties of Czech version of Parkinson Anxiety Scale (PAS), new scale developed in 2014 to measure anxiety specifically…Constipation in early de novo Parkinson’s disease: Prevalence and correlates with clinical features, imaging and non-imaging biomarkers
Objective: To explore the association between constipation and clinical features, imaging and non-imaging biomarkers in early de novo (untreated) Parkinson's disease (PD) patients. Background: Constipation…Reliability of a newly developed protocol for fiberoptic endoscopic evaluation of swallowing in Parkinson’s patients (PARK-FEES)
Objective: A new FEES protocol specified for dysphagia diagnosis among Parkinson's disease (PD) patients was recently developed in a prior two-phased study¹, which is now…Is continuous twenty four hour blood pressure monitoring a suitable tool in evaluating sleep disturbances in Parkinson’s disease?
Objective: To compare blood pressure (BP) changes in nighttime by continuous twenty four hour blood pressure monitoring (RR) as a postulated tool to describe sleep…Exploring association of GBA variants with pre-diagnostic features of PD in the PREDICT-PD cohort: A nested case-control study
Objective: To investigate the association of GBA variants with pre-diagnostic features of Parkinson's disease (PD) within the PREDICT-PD cohort. Background: Subtle motor and non-motor symptoms…α-synuclein CSF levels correlate with urinary dysfunction in early de novo Parkinson’s disease patients
Objective: To explore the association between levels of α-synuclein burden and urinary dysfunction in early de novo (untreated) Parkinson's disease (PD) patients. Background: Urinary dysfunction…The dopamine agonist withdrawal syndrome rating scale (DAWS-RS): Initial development of a new non-motor scale
Objective: To describe the development of the dopamine agonist withdrawal syndrome (DAWS) rating scale (DAWS-RS), a new questionnaire designed to evaluate the symptoms, severity, and…The prevalence of gastrointestinal disorders and non-motor symptoms in a cohort of patients with Parkinson’s disease
Objective: The aim of this investigation was to estimate the prevalence of gastrointestinal disorders (GID) and non-motor symptoms (NMS) in a cohort of a cohort…Identification of barriers preventing disclosure of non-motor symptoms in Parkinson’s patients to healthcare providers
Objective: 1) To identify patient barriers to help-seeking for non-motor symptoms (NMS) from their Parkinson's healthcare provider, 2) To determine whether barriers are symptom specific…
- « Previous Page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- 55
- Next Page »